
Frontiers in Molecular Biosciences, Год журнала: 2025, Номер 12
Опубликована: Фев. 25, 2025
The ongoing post-COVID-19 syndrome (PCS) epidemic, causing complications of diverse etiology, necessitates the search for new diagnostic markers and development widely accessible methods their detection. This would enable prognosis PCS progression faster implementation targeted treatments. One potential marker is neutrophil elastase (NE), whose elevated levels in blood during may result from organ damage caused by increased secretion severe inflammatory mediators or amyloidosis resulting interaction NE with SARS-CoV-2. aim this publication to present a step-by-step method designing an enzymatic ELISA test, enabling quantitative assessment serum patients. was measured using designed test. study outlines all steps necessary optimizing including selection standards, primary secondary antibodies, dilutions. Using were demonstrated patients advanced-stage diabetic nephropathy after symptomatic COVID-19, compared relative group sampled before COVID-19. undertaken efforts enabled test high performance parameters (initially set sensitivity: ≥40 pg/μL; intra-assay precision: 7%; inter-assay precision <20%). No significant cross-reactivity other tested proteins observed. Serial dilution plasma samples resulted proportional decrease signal intensity.
Язык: Английский